Compare ADMA Biologics Inc (ADMA) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs TotalEnergies SE — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while TotalEnergies SE trades at $86.9 (market cap $193.69B). The key difference: TotalEnergies SE is far larger — about 88.8× ADMA Biologics Inc's market cap, and TotalEnergies SE pays a 4.82% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | TTE | |
|---|---|---|
Market Cap | $2.18B | $193.69B |
Sector | Health | Energy |
52-Week High | $20.38 | $93.60 |
52-Week Low | $7.60 | $57.39 |
Enterprise Value | $2.25B | $224.68B |
Dividend Yield | — | 4.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
TotalEnergies (TTE) trades at $85.83, down 0.51% on the day, with a neutral technical signal. The stock shows attractive valuation metrics, including a P/E of 10.74 and P/S of 0.96, while recent earnings beat expectations in Q1 and Q2 2026. The company is actively reshaping its portfolio, acquiring Shell's European renewables business and developing the Cronos gas field in Cyprus. Cash flow improved in 2025, with net cash flow turning positive to $358 million after two years of outflows.
The outlook is supported by a strong analyst consensus, with a $94 price target and 57.6% buy ratings, but risks include declining revenue trends, legal challenges from climate litigation, and exposure to volatile energy markets. The stock offers a compelling value proposition with solid profitability and strategic investments in both traditional and renewable energy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
